Drug facts
BrandAnoro Ellipta (Umeclidinium and Vilanterol)
No generic umeclidinium and vilanterol is approved; the latest Anoro Ellipta patent or exclusivity in the Orange Book runs to 11/29/2030.
Anoro Ellipta was first approved by the FDA on 12/18/2013 under NDA 203975; the application holder is Glaxosmithkline Intellectual Property Development Ltd England.
The latest NADAC for ANORO ELLIPTA 62.5-25 MCG INH is $7.80 per unit (as of 10/28/2026).
Holder Glaxosmithkline Intellectual Property Development Ltd EnglandApplication NDA 203975Approved 12/18/2013
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,490days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved12/18/2013
Last patent11/29/2030
2014201720202023202620292032
- Latest patent
- 11/29/2030Anoro Ellipta Orange Book
02Competition
- Generics
- No generic approved Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Anoro Ellipta profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $7.80 per unitANORO ELLIPTA 62.5-25 MCG INH, as of 10/28/2026 CMS NADAC
- Latest recall
- 12/12/2023Class III, Umeclidinium Bromide and Vilanterol Trifenatate, Glaxosmithkline LLC FDA enforcement
04Product
- Application holder
- Glaxosmithkline Intellectual Property Development Ltd England Orange Book
- Application
- NDA 203975 Orange Book
- First approved
- 12/18/2013 Orange Book
- Dosage forms
- powder
- Routes
- inhalation
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.